Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 6Head and Neck Neoplasms 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 4Esophageal Squamous Cell Carcinoma 3Breast Neoplasms 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Colonic Neoplasms 2Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC 1Stage IV EGFR Mutated Non-Small Cell Lung Cancer 1Prostatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

tusamitamab ravtansine 2Gemcitabine 2pembrolizumab 1necitumumab 1Ramucirumab 1MLN 8237 1LY3023414 1Gefitinib 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Non-small Cell Lung Cancer Metastatic × Gefitinib × Clear all
NCT02299765 2017-11-27

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Sichuan University

Phase 4 Terminated
61 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡